From the interview with Dr.B that KarinCa did

"The trial for Brilacidin-OM for the prevention and/or treatment of oral mucositis in head and neck cancer patients receiving chemoradiation has moved slower than expected, simply because of competing trials. We're bringing on additional sites with less competition to quicken enrollment. I've been involved with enough clinical trials to understand that slow enrollment sometimes happens and that requires steps to address it. It has also taught me to a have a slightly different view on significance for a particular indication. Many companies are trying to develop new treatments as FDA approved drugs for oral mucositis in cancer patients. That tells me that there is a great demand and companies see the value in it. If Brilacidin-OM, with its many novel properties, is successful in this trial, I believe its value would be considerable."